ACC Updates Expert Consensus Pathway for HFpEF Management

These updates aim to refine the treatment approach for patients who maintain a relatively normal ejection fraction but still experience heart failure symptoms, according to reporting from HCPLive and tctmd.com.

HFpEF is a complex condition where the heart muscle becomes stiff and fails to fill properly during the resting phase of the cardiac cycle. Because the heart’s pumping ability (ejection fraction) remains preserved, diagnosis and treatment have historically been more challenging than in heart failure with reduced ejection fraction (HFrEF).

The updated ACC pathway focuses on a multidisciplinary approach to reduce hospitalizations and improve the quality of life for these patients by targeting comorbidities and specific drug classes that show efficacy in this population.

Expanded Role of Finerenone and GLP-1 Receptor Agonists

The updated consensus pathway provides a boost to the use of finerenone, a nonsteroidal mineralocorticoid receptor antagonist. According to tctmd.com, the ACC’s revised guidance reflects a stronger emphasis on this medication to manage fluid retention and protect kidney function in HFpEF patients, particularly those with chronic kidney disease.

The ACC also emphasized the integration of GLP-1 receptor agonists into the management strategy. These medications, traditionally used for type 2 diabetes and weight loss, are highlighted in the updated pathway due to their potential to reduce cardiovascular risk and manage obesity, which is a primary driver of HFpEF development.

By prioritizing these therapies, the ACC aims to move beyond simple diuretic therapy, which manages symptoms of congestion but does not necessarily alter the progression of the disease.

Revised Management Strategies for HFpEF

The revised decision pathway outlines a structured approach to treatment that begins with the stabilization of fluid levels and the management of underlying conditions. According to HCPLive, the updated guidance underscores the importance of treating hypertension and diabetes aggressively to prevent further cardiac remodeling.

The pathway includes specific considerations for different patient phenotypes, acknowledging that HFpEF is not a monolithic disease. Factors such as age, obesity, and the presence of atrial fibrillation now play a more defined role in determining which therapeutic agents a clinician should prioritize.

SGLT2 inhibitors remain a cornerstone of the HFpEF strategy, but the new consensus provides clearer instructions on how to layer other therapies, such as finerenone and GLP-1s, onto this foundation to maximize patient outcomes.

Clinical Impact and Patient Outcomes

The shift toward these specific pharmacological interventions is driven by a need to lower the rate of heart failure-related hospitalizations. According to tctmd.com, the emphasis on GLP-1s is particularly relevant for the “obese HFpEF” phenotype, where weight loss and metabolic control are directly linked to improved cardiac function.

The ACC’s updated pathway suggests that a combination of SGLT2 inhibitors and the newly emphasized agents may provide a more comprehensive defense against the progression of heart failure. This approach targets both the hemodynamic issues of the heart and the systemic metabolic issues that contribute to heart stiffness.

Clinicians are encouraged to use the updated decision pathway to personalize care, moving away from a one-size-fits-all model of diuretic use toward a targeted, multi-drug regimen based on the patient’s specific comorbidities.